Brought to you by 
ArQule gets $75mm up front in two new deals with Daiichi; certain rights returned to ArQule
25 Jan 2016
Executive Summary
ArQule (oncology therapeutics) and Daiichi Sankyo (Japanese pharmaco developing treatments for cardiovascular diseases, diabetes, autoimmune disorders, cancer, and infections) have entered into two cancer deals that together provide ArQule with $75mm up front and the potential for up to $560mm in milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ArQule gets $75mm up front in two new deals with Daiichi; certain rights returned to ArQule
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice